keyboard_arrow_up

In-Depth Report on Hemophilia A - Pipeline Review, H2 2015

Hemophilia A - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Hemophilia A’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects.

The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. 

To access full report with TOC, please visit ​Hemophilia A - Pipeline Review, H2 2015.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemophilia A
- The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Alnylam Pharmaceuticals, Inc. Amarna Therapeutics B.V. Apitope International NV AstraZeneca Plc Baxalta Incorporated Bayer AG Biogen, Inc. BioMarin Pharmaceutical Inc. Catalyst Biosciences, Inc. Celtic Pharmaceutical Holdings L.P. CSL Limited DBV Technologies S.A. Dimension Therapeutics, Inc. Dong-A Socio Group Emergent BioSolutions Inc. EpiVax, Inc. Expression Therapeutics LLC F. Hoffmann-La Roche Ltd. Green Cross Corporation Inbiopro Solutions Pvt. Ltd. Lentigen Technology, Inc. mAbxience S.A. Novo Nordisk A/S OPKO Health, Inc. Pfizer Inc. Pharming Group N.V. rEVO Biologics, Inc. Sangamo BioSciences, Inc. Selecta Biosciences, Inc. SK Chemicals Co., Ltd. Spark Therapeutics, Inc. The International Biotechnology Center (IBC) Generium uniQure N.V.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###